Greywolf Therapeutics
UK - OxfordBiotechnology
Focus: Greywolf Therapeutics is a UK-based biotech specialist in immuno-oncology, focused on modulating ERAP1 and ERAP2 to reactivate immune responses against solid tumors. The company is at Series B stage with emerging clinical validation in hard-to-treat cancers.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Total Funding
$131M
Open Jobs
1
Should You Work at Greywolf Therapeutics?
AI assessmentAn attractive early-stage immuno-oncology opportunity with recent clinical momentum, but limited public financial transparency and narrow apparent pipeline warrant due diligence on runway and growth plans.
Why Work Here
- Recent ASCO trial data (June 2026) demonstrates 30%+ tumor shrinkage with lead candidate GRWD5769, providing near-term validation of the ERAP modulation mechanism.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Greywolf Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.